Moderna Inc (MRNA) has had recent significant developments in its pipeline. The mRNA technology has demonstrated its capability to combat a range of health conditions including COVID-19, Rare heart conditions, and solid tumours. Despite the drop in Moderna's stock, the company continues to draw attention with its Moderna’s mRNA solid tumour vaccine showcasing early promise and the development of its mRNA bird flu vaccine backed by a $176 million grant from the U.S. Government. Additionally, the administration expresses concerns of Pfizer's and Moderna's mRNA Covid vaccines' effects on Vulnerable Individuals due to concerns related to rare heart conditions. On the other hand, some tough market conditions have led to Moderna announcing cuts in its R&D spending and dropping several programs. Despite this, Jim Cramer, American television personality, advises investors to consider Moderna a 'Strong Buy' due to its vaccine pipeline and cancer advances.
Moderna MRNA News Analytics from Fri, 01 Mar 2024 08:00:00 GMT to Fri, 11 Oct 2024 15:57:03 GMT -
Rating 1
- Innovation 9
- Information 8
- Rumor 5
